0001171843-18-001105.txt : 20180213
0001171843-18-001105.hdr.sgml : 20180213
20180213165248
ACCESSION NUMBER: 0001171843-18-001105
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180213
FILED AS OF DATE: 20180213
DATE AS OF CHANGE: 20180213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON JOHN
CENTRAL INDEX KEY: 0001410781
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33609
FILM NUMBER: 18604349
MAIL ADDRESS:
STREET 1: DENDREON CORPORATION
STREET 2: 1301 2ND AVENUE
CITY: SEATTLE
STATE: WA
ZIP: 98101
FORMER NAME:
FORMER CONFORMED NAME: Johnson John H
DATE OF NAME CHANGE: 20070827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sucampo Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001365216
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133929237
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 805 KING FARM BOULEVARD, SUITE 550
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 3019613400
MAIL ADDRESS:
STREET 1: 805 KING FARM BOULEVARD, SUITE 550
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
form4.xml
OWNERSHIP DOCUMENT
X0306
4
2018-02-13
1
0001365216
Sucampo Pharmaceuticals, Inc.
SCMP
0001410781
JOHNSON JOHN
805 KING FARM BLVD, SUITE 550
ROCKVILLE
MD
20850
1
0
0
0
Common Stock, Class A
2018-02-13
4
D
0
5130
18.00
D
0
D
Director Stock Option (right to buy)
13.92
2018-02-13
4
D
0
30000
4.08
D
2024-12-10
Common Stock
30000
0
D
Director Stock Option (right to buy)
16.23
2018-02-13
4
D
0
20000
1.77
D
2025-05-29
Common Stock
20000
0
D
Director Stock Option (right to buy)
10.30
2018-02-13
4
D
0
10000
7.70
D
2025-05-29
Common Stock
10000
0
D
This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement.
This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
/s/ John H. Johnson
2018-02-13